Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

Avalo Therapeutics, Inc.

AVTXNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1.…

Filed Aug 6, 2026Accepted Aug 6, 2026, 7:01 AM EDTCIK 1534120Accession 0001534120-26-000048
Share

Company context

Current securities

Historical securities (2)

Recent company filings

  1. 144 filingAug 17, 2026
  2. SCHEDULE 13G/A filingAug 14, 2026
  3. SCHEDULE 13G/A filingAug 14, 2026
  4. SCHEDULE 13G/A filingAug 14, 2026
  5. SCHEDULE 13G/A filingAug 14, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.